Welcome to our dedicated page for AC Immune SA news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune SA stock.
AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, committed to pioneering precision medicine for neurodegenerative diseases. The company specializes in designing, discovering, and developing innovative therapeutic and diagnostic products aimed at preventing and modifying diseases caused by misfolded proteins. Utilizing its two proprietary technology platforms, SupraAntigen® and Morphomer®, AC Immune develops a broad spectrum of antibodies, small molecules, and vaccines targeting conditions such as Alzheimer’s disease (AD), Parkinson’s disease, and NeuroOrphan indications.
With a robust pipeline consisting of sixteen therapeutic and diagnostic programs, AC Immune currently has six product candidates in clinical trials, including five in Phase 2 and one in Phase 3. The most advanced candidate, Crenezumab, is a humanized anti-amyloid-β monoclonal antibody in Phase 3 trials aimed at treating Alzheimer’s disease. Other notable candidates include ACI-24.060, a promising anti-Abeta active immunotherapy for AD and Down syndrome, which has received FDA Fast Track Designation, and ACI-35.030, an anti-pTau active immunotherapy in Phase 2b trials for preclinical AD conducted by Janssen Pharmaceuticals.
Beyond its rich pipeline, AC Immune is known for its strategic partnerships with leading global pharmaceutical companies such as Genentech (a Roche Group member), Eli Lilly and Company, and Takeda. These collaborations have resulted in significant non-dilutive funding and milestone payments totaling over $4.5 billion.
AC Immune recently secured an exclusive option and license agreement with Takeda for its ACI-24.060 product, potentially worth $2.1 billion, and completed a $50 million equity financing to support its operations into 2026. The company's focused efforts on precision prevention are reinforced by its ongoing Phase 2 trials and collaborations aimed at leveraging advanced diagnostic techniques like PET imaging and novel therapeutic approaches for early and effective intervention in neurodegenerative diseases.
AC Immune will host a Key Opinion Leader webinar focused on the early diagnosis and prevention of Alzheimer’s disease on April 18, 2023, at 10:30 AM EDT / 4:30 PM CEST. CEO Andrea Pfeifer will kick off the session, introducing speakers Dr. Kaj Blennow and Dr. Giovanni Frisoni, who will discuss advancements in Alzheimer’s detection and the potential of therapeutic vaccines. The presentations will detail AC Immune's Precision Medicine approach and highlight clinical-stage vaccines targeting amyloid-beta and phosphorylated Tau. A Q&A session will follow. Interested participants can register here.
AC Immune announced ten presentations at the AD/PD™ 2023 conference in Gothenburg, Sweden, from March 28 to April 1, 2023. The company is focused on precision medicine for neurodegenerative diseases, highlighting progress in Alzheimer's and Parkinson's treatments. Chief Medical Officer Johannes Streffer will discuss immunotherapies at the event. The CEO emphasized the advancements in their vaccine pipeline and the potential for significant market impact. AC Immune's pipeline includes first- and best-in-class assets, with several candidates in Phase 2 and 3 clinical trials, underscoring their commitment to innovative treatments.
AC Immune reported its 2022 financial results showcasing a cash position of CHF 122.6 million, providing runway into Q3 2024. The company recorded CHF 3.9 million in contract revenues, a significant increase from zero in the prior year. R&D expenditures decreased to CHF 60.3 million, primarily due to advancements in clinical studies for ACI-24.060. The net loss was CHF 70.8 million, a slight improvement from CHF 73.0 million in 2021. Looking ahead, the company anticipates a cash burn of CHF 65 to CHF 75 million for 2023, and milestones for its anti-amyloid and anti-Tau vaccine developments are set for 2023.
AC Immune (NASDAQ: ACIU) has announced a press release to report its full year 2022 financial results and provide a corporate update on March 16, 2023, at 7:00 am ET. After the announcement, management will be available for one-on-one calls with investors and analysts to discuss the results and outlook for 2023. The company focuses on precision medicine for neurodegenerative diseases, utilizing its two technology platforms, SupraAntigen® and Morphomer®, and has a robust pipeline with ten therapeutic and three diagnostic candidates.
AC Immune has secured significant funding through grants from The Michael J. Fox Foundation and Target ALS Foundation totaling over USD 500,000. The grants will support the development of a first-in-class TDP-43 PET tracer and innovative biofluid assays for TDP-43-related neuropathology, crucial in neurodegenerative diseases like ALS and FTLD. The MJFF grant aims to facilitate the creation of the first imaging agent for TDP-43, while the Target ALS grant promotes collaboration among major institutions to enhance diagnostic capabilities. These initiatives align with AC Immune's precision medicine strategy to revolutionize early diagnosis and treatment in the neurodegenerative disease sector.
AC Immune will participate in the SVB Securities Global Biopharma Conference from February 14-16, 2023. Management will engage in a fireside chat on February 14 at 8:40 AM ET / 2:40 PM CET, where CEO Dr. Andrea Pfeifer will outline the company's precision medicine approach and pipeline, which includes 16 therapeutic and diagnostic programs. Notably, the ACI-24.060 vaccine has shown positive results in initial trials for Alzheimer’s disease. A replay of the presentation will be available on AC Immune’s events page after the live event.
FAQ
What is the current stock price of AC Immune SA (ACIU)?
What is the market cap of AC Immune SA (ACIU)?
What is AC Immune's primary focus?
What are AC Immune's most advanced product candidates?
What technology platforms does AC Immune use?
Who are AC Immune's strategic partners?
What is the significance of the recent agreement with Takeda?
How is AC Immune funded?
What is AC Immune’s financial outlook?
What ongoing clinical trials is AC Immune conducting?
What recent milestones has AC Immune achieved?
How does AC Immune contribute to the field of neurodegenerative disease research?
